BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class ...

Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumorsPreclinical ...

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its ...

Nonpathogenic E. coli displaying decoy-resistant IL18 demonstrate potent anti-tumor responses and boost CAR-NK cell ...

Title: NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naive MSS/MSI-L colorectal cancer (CRC) Lead Author: ...

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) ...

A phase 2/3 non-inferiority study compared de-escalation strategies to standard chemoradiation in patients with human ...

A new study published in Cell Reports Medicine reveals critical insights into the role of gamma-delta T cells across 33 ...

Recent advancements in cancer treatment, including Precision Medicine, Immunotherapy, and Targeted Therapy, are leading to improved patient outcomes.

A new study published in Cell Press reveals critical insights into the role of gamma-delta T cells across 33 cancer types, ...

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer ...

Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery ...